Cetuximab

Generic Name
Cetuximab
Brand Names
Erbitux
Drug Type
Biotech
Chemical Formula
-
CAS Number
205923-56-4
Unique Ingredient Identifier
PQX0D8J21J
Background

Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...

Indication

Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...

Associated Conditions
Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Associated Therapies
-
Clinical Trials
Related News

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

First Posted Date
2021-01-22
Last Posted Date
2024-11-22
Lead Sponsor
Sanofi
Target Recruit Count
456
Registration Number
NCT04717375
Locations
🇺🇸

Mayo Clinic Hospital- Site Number : 8400003, Phoenix, Arizona, United States

🇺🇸

City of Hope Comprehensive Cancer Center- Site Number : 8400002, Duarte, California, United States

🇺🇸

Smilow Cancer Center at Yale-New Haven- Site Number : 8400001, New Haven, Connecticut, United States

and more 14 locations

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

First Posted Date
2020-12-17
Last Posted Date
2022-03-23
Lead Sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Target Recruit Count
531
Registration Number
NCT04672772
Locations
🇪🇸

Hospital Universitario Canarias (TENERIFE), San Cristobal de la Laguna, Tenerife, Spain

🇪🇸

Hospital Universitario Clínico San Carlos, Madrid, Spain

🇪🇸

Hospital Regional Universitario de Málaga, Málaga, Andalucia, Spain

and more 17 locations

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

First Posted Date
2020-12-17
Last Posted Date
2024-08-27
Lead Sponsor
Erasca, Inc.
Target Recruit Count
200
Registration Number
NCT04670679
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Washington University, Saint Louis, Missouri, United States

and more 12 locations

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

First Posted Date
2020-12-17
Last Posted Date
2022-09-29
Lead Sponsor
Pierre Fabre Pharma GmbH
Target Recruit Count
500
Registration Number
NCT04673955
Locations
🇩🇪

Prctice, Naunhof, Sachsen, Germany

🇩🇪

Private Practice, Würzburg, Germany

🇩🇪

Clinic, Berlin, Germany

and more 5 locations

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Phase 2
Withdrawn
Conditions
Lung Cancer
Surgery
Circulating Tumor Cell
Interventions
Drug: Cetuximab
First Posted Date
2020-12-01
Last Posted Date
2023-10-19
Lead Sponsor
The Netherlands Cancer Institute
Registration Number
NCT04648189
Locations
🇳🇱

Amsterdam UMC - VUMC, Amsterdam, Netherlands

🇳🇱

Leiden University Medical Center, Leiden, Netherlands

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

First Posted Date
2020-11-04
Last Posted Date
2024-10-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
46
Registration Number
NCT04616183
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

First Posted Date
2020-11-04
Last Posted Date
2024-05-13
Lead Sponsor
Nektar Therapeutics
Target Recruit Count
25
Registration Number
NCT04616196
Locations
🇺🇸

University of California, San Diego, San Diego, California, United States

🇺🇸

START Center for Cancer Care, San Antonio, Texas, United States

🇺🇸

Mary Crowley Cancer Research, Dallas, Texas, United States

and more 3 locations

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

First Posted Date
2020-10-29
Last Posted Date
2024-12-17
Lead Sponsor
Pfizer
Target Recruit Count
816
Registration Number
NCT04607421
Locations
🇺🇸

LAC & USC Medical Center, Los Angeles, California, United States

🇺🇸

Cedars- Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Investigational Drug Service, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

and more 378 locations

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

First Posted Date
2020-10-19
Last Posted Date
2024-11-15
Lead Sponsor
AstraZeneca
Target Recruit Count
370
Registration Number
NCT04590963
Locations
🇬🇧

Research Site, Sutton, United Kingdom

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

First Posted Date
2020-10-14
Last Posted Date
2024-04-30
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
71
Registration Number
NCT04587128
Locations
🇺🇸

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy